Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Paulson Richard A. | President and CEO | Oct 04 '24 | Sale | 0.88 | 3,607 | 3,172 | 1,135,607 | Oct 07 04:44 PM | Mano Michael | SVP, General Counsel&Secretary | Sep 04 '24 | Sale | 0.72 | 3,971 | 2,866 | 273,881 | Sep 05 04:28 PM | Paulson Richard A. | President and CEO | Sep 04 '24 | Sale | 0.72 | 3,667 | 2,647 | 1,139,214 | Sep 05 04:26 PM | Mason Michael | EVP, CFO & Treasurer | Sep 04 '24 | Sale | 0.72 | 7,050 | 5,089 | 391,054 | Sep 05 04:24 PM | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | Sep 04 '24 | Sale | 0.72 | 5,356 | 3,866 | 404,051 | Sep 05 04:13 PM | Paulson Richard A. | President and CEO | Aug 06 '24 | Sale | 0.93 | 3,608 | 3,355 | 1,142,881 | Aug 08 04:31 PM | Poulton Stuart | EVP, Chief Development Officer | Jul 30 '24 | Sale | 1.06 | 2,883 | 3,056 | 326,628 | Jul 31 04:14 PM | Paulson Richard A. | President and CEO | Jul 05 '24 | Sale | 0.85 | 3,616 | 3,077 | 1,146,489 | Jul 09 04:15 PM | PAKIANATHAN DEEPIKA | Director | Jun 05 '24 | Sale | 0.96 | 468,044 | 448,480 | 3,385 | Jun 07 07:18 PM | PAKIANATHAN DEEPIKA | Director | Jun 07 '24 | Sale | 0.95 | 231,548 | 220,133 | 0 | Jun 07 07:18 PM | PAKIANATHAN DEEPIKA | Director | Jun 06 '24 | Sale | 0.98 | 118,452 | 116,415 | 2,240 | Jun 07 07:18 PM | Mason Michael | EVP, CFO & Treasurer | Jun 04 '24 | Sale | 0.99 | 652 | 645 | 398,104 | Jun 06 04:03 PM | Paulson Richard A. | President and CEO | Jun 04 '24 | Sale | 0.99 | 3,592 | 3,556 | 1,150,105 | Jun 06 04:02 PM | PAKIANATHAN DEEPIKA | Director | Jun 03 '24 | Sale | 1.00 | 360,744 | 360,997 | 11,209 | Jun 04 06:51 PM | PAKIANATHAN DEEPIKA | Director | Jun 04 '24 | Sale | 0.95 | 341,040 | 324,704 | 7,911 | Jun 04 06:51 PM | PAKIANATHAN DEEPIKA | Director | May 31 '24 | Sale | 0.95 | 204,394 | 194,992 | 14,697 | Jun 04 06:51 PM | Paulson Richard A. | President and CEO | May 06 '24 | Sale | 1.13 | 3,576 | 4,041 | 1,153,697 | May 07 04:56 PM | Rangwala Reshma | EVP & Chief Medical Officer | Apr 22 '24 | Sale | 1.17 | 6,789 | 7,943 | 342,931 | Apr 23 04:02 PM | Paulson Richard A. | President and CEO | Apr 04 '24 | Sale | 1.29 | 3,563 | 4,596 | 1,157,273 | Apr 05 05:20 PM | Paulson Richard A. | President and CEO | Mar 05 '24 | Sale | 1.30 | 3,573 | 4,645 | 1,160,836 | Mar 06 04:14 PM | Rangwala Reshma | EVP & Chief Medical Officer | Feb 29 '24 | Sale | 1.17 | 15,667 | 18,330 | 355,689 | Mar 04 07:41 PM | Rangwala Reshma | EVP & Chief Medical Officer | Mar 01 '24 | Sale | 1.20 | 5,969 | 7,163 | 349,720 | Mar 04 07:41 PM | Poulton Stuart | EVP, Chief Development Officer | Feb 29 '24 | Sale | 1.17 | 16,311 | 19,084 | 335,666 | Mar 04 07:40 PM | Poulton Stuart | EVP, Chief Development Officer | Mar 01 '24 | Sale | 1.20 | 6,155 | 7,386 | 329,511 | Mar 04 07:40 PM | Mason Michael | EVP, CFO & Treasurer | Feb 29 '24 | Sale | 1.17 | 27,687 | 32,394 | 404,918 | Mar 04 07:39 PM | Mason Michael | EVP, CFO & Treasurer | Mar 01 '24 | Sale | 1.20 | 6,162 | 7,394 | 398,756 | Mar 04 07:39 PM | Mano Michael | SVP, General Counsel&Secretary | Feb 29 '24 | Sale | 1.17 | 16,973 | 19,858 | 281,428 | Mar 04 07:38 PM | Mano Michael | SVP, General Counsel&Secretary | Mar 01 '24 | Sale | 1.20 | 3,576 | 4,291 | 277,852 | Mar 04 07:38 PM | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | Feb 29 '24 | Sale | 1.17 | 21,840 | 25,553 | 398,618 | Mar 04 07:37 PM | Cheng Sohanya Roshan | EVP & Chief Commercial Officer | Mar 01 '24 | Sale | 1.20 | 5,109 | 6,131 | 393,509 | Mar 04 07:37 PM | Paulson Richard A. | President and CEO | Feb 29 '24 | Sale | 1.17 | 80,470 | 94,150 | 1,183,783 | Mar 04 07:36 PM | Paulson Richard A. | President and CEO | Mar 01 '24 | Sale | 1.20 | 19,374 | 23,249 | 1,164,409 | Mar 04 07:36 PM | Mason Michael | EVP, CFO & Treasurer | Feb 27 '24 | Sale | 1.32 | 2,545 | 3,369 | 244,400 | Feb 29 05:35 PM | Poulton Stuart | EVP, Chief Development Officer | Feb 15 '24 | Sale | 1.33 | 5,847 | 7,783 | 163,772 | Feb 20 04:59 PM | Mason Michael | EVP, CFO & Treasurer | Feb 06 '24 | Sale | 1.59 | 4,205 | 6,671 | 246,945 | Feb 08 04:36 PM | Paulson Richard A. | President and CEO | Feb 06 '24 | Sale | 1.59 | 4,012 | 6,365 | 821,453 | Feb 08 04:34 PM | Paulson Richard A. | President and CEO | Jan 04 '24 | Sale | 0.82 | 4,114 | 3,373 | 783,465 | Jan 08 09:00 PM | Paulson Richard A. | President and CEO | Dec 04 '23 | Sale | 0.79 | 3,622 | 2,861 | 787,579 | Dec 05 05:03 PM | Paulson Richard A. | President and CEO | Nov 06 '23 | Sale | 0.92 | 3,606 | 3,319 | 791,201 | Nov 07 05:32 PM |
|